Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection - PubMed (original) (raw)
. 2010 Jun 15;201(12):1788-95.
doi: 10.1086/652749.
David R Jacobs Jr, Jason V Baker, Alexandra Calmy, Daniel Duprez, Alberto La Rosa, Lewis H Kuller, Sarah L Pett, Matti Ristola, Michael J Ross, Michael G Shlipak, Russell Tracy, James D Neaton
Affiliations
- PMID: 20446848
- PMCID: PMC2872049
- DOI: 10.1086/652749
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection
Jacqueline Neuhaus et al. J Infect Dis. 2010.
Abstract
Background: Human immunodeficiency virus (HIV) replication and immune activation may increase inflammation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without HIV infection.
Methods: For persons 45-76 years of age, levels of high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, D-dimer, and cystatin C were compared in 494 HIV-infected individuals in the Strategies for Management of Anti-Retroviral Therapy (SMART) study and 5386 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) study. For persons 33-44 years of age, hsCRP and IL-6 levels were compared in 287 participants in the SMART study and 3231 participants in the Coronary Artery Development in Young Adults (CARDIA) study.
Results: hsCRP and IL-6 levels were 55% (P < . 001) and 62 (P < . 001) higher among HIV-infected participants than among CARDIA study participants. Compared with levels noted in MESA study participants, hsCRP, IL-6, D-dimer, and cystatin C levels were 50%, 152%, 94%, and 27% higher, respectively (P < . 001, for each), among HIV-infected participants. HIV-infected participants receiving antiretroviral therapy who had HIV RNA levels 400 copies/mL had levels higher (by 21% to 60%) (P < . 001) than those in the general population, for all biomarkers.
Conclusions: hsCRP, IL-6, D-dimer, and cystatin C levels are elevated in persons with HIV infection and remain so even after HIV RNA levels are suppressed with antiretroviral therapy. Additional research is needed on the pathophysiology of HIV-induced activation of inflammatory and coagulation pathways, to guide potential interventions.
Conflict of interest statement
Russell Tracy reports being a paid Consultant to Abbott and Merck. No other authors have a commercial or other association that might pose a conflict of interest.
Figures
Figure 1
Figure 1a: Percentage Difference (HIV-infected versus General Population for hsCRP and IL-6): Participants Aged 33–44 Years. Figure 1b: Percentage Difference (HIV-infected versus General Population for hsCRP, IL-6, D-dimer and Cystatin C): Participants Aged 45–76 Years.
Figure 1
Figure 1a: Percentage Difference (HIV-infected versus General Population for hsCRP and IL-6): Participants Aged 33–44 Years. Figure 1b: Percentage Difference (HIV-infected versus General Population for hsCRP, IL-6, D-dimer and Cystatin C): Participants Aged 45–76 Years.
Comment in
- Inflammation and complications of HIV disease.
Dubé MP, Sattler FR. Dubé MP, et al. J Infect Dis. 2010 Jun 15;201(12):1783-5. doi: 10.1086/652751. J Infect Dis. 2010. PMID: 20446849 No abstract available.
Similar articles
- Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.
Borges ÁH, Weitz JI, Collins G, Baker JV, Lévy Y, Davey RT Jr, Phillips AN, Neaton JD, Lundgren JD, Deeks SG; INSIGHT SILCAAT Scientific Committee. Borges ÁH, et al. AIDS. 2014 Jul 31;28(12):1791-6. doi: 10.1097/QAD.0000000000000344. AIDS. 2014. PMID: 25003720 Free PMC article. - Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators. Wilson EM, et al. J Infect Dis. 2014 Nov 1;210(9):1396-406. doi: 10.1093/infdis/jiu275. Epub 2014 May 9. J Infect Dis. 2014. PMID: 24813472 Free PMC article. - Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Kuller LH, et al. PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203. PLoS Med. 2008. PMID: 18942885 Free PMC article. - Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients.
Funderburg NT. Funderburg NT. Curr Opin HIV AIDS. 2014 Jan;9(1):80-6. doi: 10.1097/COH.0000000000000019. Curr Opin HIV AIDS. 2014. PMID: 24275673 Free PMC article. Review. - Cardiovascular Complications of HIV-Associated Immune Dysfunction.
Zaaqoq AM, Khasawneh FA, Smalligan RD. Zaaqoq AM, et al. Cardiol Res Pract. 2015;2015:302638. doi: 10.1155/2015/302638. Epub 2015 Jan 11. Cardiol Res Pract. 2015. PMID: 25648075 Free PMC article. Review.
Cited by
- The Negative Impact of Maternal HIV Infection on Birth Outcomes-Myth or Reality?
Fleșeriu T, Meliț LE, Mărginean CO, Văsieșiu AM. Fleșeriu T, et al. Pathogens. 2024 Sep 18;13(9):808. doi: 10.3390/pathogens13090808. Pathogens. 2024. PMID: 39338999 Free PMC article. - HIV-1 controllers exhibit an enhanced antiretroviral innate state characterised by overexpression of p21 and MCPIP1 and silencing of ERVK-6 RNA expression.
de Azevedo SSD, Ribeiro-Alves M, Côrtes FH, Delatorre E, Hoagland B, Villela LM, Grinsztejn B, Veloso VG, Morgado MG, Souza TML, Bello G. de Azevedo SSD, et al. Mem Inst Oswaldo Cruz. 2024 Sep 16;119:e240071. doi: 10.1590/0074-02760240071. eCollection 2024. Mem Inst Oswaldo Cruz. 2024. PMID: 39292108 Free PMC article. - Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
Cyktor JC, Yeh E, Ribaudo H, Hoeth D, Naqvi A, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Tawakol A, Lederman MM, Stein JH, Deeks SG, Currier JS, Hsue PY, Mellors JW; A5314 Team. Cyktor JC, et al. J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):481-485. doi: 10.1097/QAI.0000000000003453. J Acquir Immune Defic Syndr. 2024. PMID: 39287554 Clinical Trial. - A systematic review assessing the association of inflammatory markers with kidney dysfunction in people living with HIV on highly active antiretroviral therapy.
Choshi J, Hanser S, Mabhida SE, Mokoena H, Moetlediwa MT, Muvhulawa N, Sekgala MD, Nkambule BB, Mchiza ZJR, Ndwandwe D, Nqebelele U, Kengne AP, Dludla PV. Choshi J, et al. BMC Infect Dis. 2024 Aug 2;24(1):776. doi: 10.1186/s12879-024-09594-5. BMC Infect Dis. 2024. PMID: 39095687 Free PMC article. - A Perfect Storm: The Convergence of Aging, Human Immunodeficiency Virus Infection, and Inflammasome Dysregulation.
Thirugnanam S, Rout N. Thirugnanam S, et al. Curr Issues Mol Biol. 2024 May 15;46(5):4768-4786. doi: 10.3390/cimb46050287. Curr Issues Mol Biol. 2024. PMID: 38785555 Free PMC article. Review.
References
- The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count – guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–22296. - PubMed
- Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871–881. - PubMed
- Cutter GR, Burke GL, Dyer AR, Friedman GD, Hilner JE, et al. Cardiovascular Risk Factors in Young Adults. The CARDIA Baseline Monograph. Cont Clin Trials. 1991;12(Supplement):1S–78S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01AI46362/AI/NIAID NIH HHS/United States
- N01 HC048050/HC/NHLBI NIH HHS/United States
- U01 AI046362-01/AI/NIAID NIH HHS/United States
- N01HC95169/HL/NHLBI NIH HHS/United States
- N01 HC095161/HC/NHLBI NIH HHS/United States
- N01 HC095164/HC/NHLBI NIH HHS/United States
- N01-HC-95159/HC/NHLBI NIH HHS/United States
- R01 DK078510/DK/NIDDK NIH HHS/United States
- N01 HC048049/HC/NHLBI NIH HHS/United States
- N01HC95095/HL/NHLBI NIH HHS/United States
- N01 HC095169/HC/NHLBI NIH HHS/United States
- N01 HC095165/HC/NHLBI NIH HHS/United States
- N01HC48050/HL/NHLBI NIH HHS/United States
- U01 AI042170/AI/NIAID NIH HHS/United States
- N01 HC095163/HC/NHLBI NIH HHS/United States
- N01-HC-48048/HC/NHLBI NIH HHS/United States
- N01 HC095162/HC/NHLBI NIH HHS/United States
- U01 AI042170-12/AI/NIAID NIH HHS/United States
- U01AI042170/AI/NIAID NIH HHS/United States
- N01 HC048047/HC/NHLBI NIH HHS/United States
- N01 HC095167/HC/NHLBI NIH HHS/United States
- N01 HC048048/HC/NHLBI NIH HHS/United States
- N01-HC-48047/HC/NHLBI NIH HHS/United States
- N01HC48049/HL/NHLBI NIH HHS/United States
- N01 HC095166/HC/NHLBI NIH HHS/United States
- N01-HC-95095/HC/NHLBI NIH HHS/United States
- N01 HC095160/HC/NHLBI NIH HHS/United States
- N01-HC-48050/HC/NHLBI NIH HHS/United States
- N01 HC095095/HC/NHLBI NIH HHS/United States
- U01 AI046362/AI/NIAID NIH HHS/United States
- N01-HC-95169/HC/NHLBI NIH HHS/United States
- MC_U122886352/MRC_/Medical Research Council/United Kingdom
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01-HC-48049/HC/NHLBI NIH HHS/United States
- N01HC48047/HL/NHLBI NIH HHS/United States
- N01 HC095168/HC/NHLBI NIH HHS/United States
- N01 HC095159/HC/NHLBI NIH HHS/United States
- N01HC48048/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials